Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
Recruiting
Observational Study
Cutaneous Melanoma
Cutaneous Melanoma, Stage III
Cutaneous Melanoma by AJCC V7 Stage
Cutaneous Melanoma, Stage IV
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 300 (estimated)
- Sponsor
- University of California, San Francisco · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The introduction of immune checkpoint inhibitors (ICIs) for the treatment of patients with stages IIB to IV cutaneous melanoma resulted in dramatic improvements in mortality rates for this common form of cancer. With this rapid shift in treatment, significant gaps in knowledge exist regarding the impact of ICIs on patients' symptom experiences. An in-depth characterization of inter-individual diff…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults ≥18 years of age
* Able to speak and read English
* Diagnosed with stage IIB, III, or IV cutaneous melanoma
* Participants who are scheduled to receive \>=1 immune checkpoint inhibitor at University of California San Francisco medical center locations. Participants on t…
Contacts